NASDAQ:ABVX Abivax Q2 2025 Earnings Report $121.37 -3.28 (-2.63%) As of 11:00 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Abivax EPS ResultsActual EPS-$0.86Consensus EPS -$0.90Beat/MissBeat by +$0.04One Year Ago EPSN/AAbivax Revenue ResultsActual RevenueN/AExpected Revenue$1.35 millionBeat/MissN/AYoY Revenue GrowthN/AAbivax Announcement DetailsQuarterQ2 2025Date9/8/2025TimeAfter Market ClosesConference Call DateMonday, September 8, 2025Conference Call Time11:45AM ETUpcoming EarningsAbivax's Q1 2026 earnings is estimated for Monday, May 25, 2026, based on past reporting schedules, with a conference call scheduled at 3:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q1 2026 Earnings ReportConference Call ResourcesPress ReleaseInterim ReportEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress ReleaseInterim Report Abivax Earnings HeadlinesAbivax Buys Back $90 Million in Royalties via $45 Million ADS Offering, Keeps Cash Runway to Q4 2027May 7 at 4:51 PM | tipranks.comABIVAX (ABVX) Announces $90M Agreement to Repurchase Royalty CertificatesMay 7 at 2:21 PM | finance.yahoo.comSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a $1.75 trillion IPO - larger than Saudi Aramco and any tech offering in history. CNBC calls it 'the big market event of 2026.' According to former tech executive and angel investor Jeff Brown, there's a way to claim a stake before the public filing drops, starting with as little as $500.May 8 at 1:00 AM | Brownstone Research (Ad)Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary SharesMay 5 at 2:00 AM | globenewswire.comAbivax SA Sponsored ADR (NASDAQ:ABVX) Sees Large Decline in Short InterestMay 2, 2026 | americanbankingnews.comHere is Why Abivax (ABVX) is One of the Best Up and Coming Stocks with Highest Upside PotentialMay 1, 2026 | finance.yahoo.comSee More Abivax Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Abivax? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Abivax and other key companies, straight to your email. Email Address About AbivaxFounded in 2013 and headquartered in Paris, France, Abivax (NASDAQ:ABVX) is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles. Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders. This small molecule has completed Phase 2 studies in rheumatoid arthritis and ulcerative colitis, demonstrating promising efficacy signals and a favorable tolerability profile. In addition, Abivax is exploring obefazimod’s antiviral potential in early-stage programs targeting chronic viral infections, including HIV and hepatitis B. With operations in Europe and strategic development activities in the United States, Abivax collaborates with academic institutions and research centers to advance its pipeline. The company is led by a management team with deep expertise in biotechnology development and regulatory affairs. Under the leadership of CEO Pascal Mélin, Abivax pursues its mission to bring innovative, host-targeted therapies to patients worldwide. View Abivax ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality CheckThe AI Fear Around Datadog Stock May Have Been Completely WrongAmprius Technologies Ups the Voltage on Forward OutlookWhy Lam Research Still Looks Like a Buy After a 300% RallyIonQ Just Posted a Breakout Quarter—But 1 Problem RemainsSLB’s Tough Quarter Masks a Powerful Long-Term ShiftSuper Micro Surges Over 20% as Margins Soar, Sales Fall Short Upcoming Earnings Constellation Energy (5/11/2026)Barrick Mining (5/11/2026)Petroleo Brasileiro S.A.- Petrobras (5/11/2026)Simon Property Group (5/11/2026)SEA (5/12/2026)Cisco Systems (5/13/2026)Alibaba Group (5/13/2026)Manulife Financial (5/13/2026)Sumitomo Mitsui Financial Group (5/13/2026)Takeda Pharmaceutical (5/13/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
